Keywords
vaccine deliver, biometrics, identity, immunizations, health systems strengthening, health service deliver, COVID-19, COVID-19 vaccine, SARS-COV-2 vaccine, SARS-COV-2
This article is included in the Coronavirus (COVID-19) collection.
vaccine deliver, biometrics, identity, immunizations, health systems strengthening, health service deliver, COVID-19, COVID-19 vaccine, SARS-COV-2 vaccine, SARS-COV-2
As we get closer and closer to an effective SARS-CoV-2 vaccine, policymakers, academics, and scientists around the globe are turning their attention to yet another fundamental challenge - how will governments monitor and verify vaccine delivery.
An effective vaccination program will falter if we don’t invest in the information infrastructure for vaccine delivery in developed and low and middle-income countries alike. There is little evidence that we are ready for this. Glaring data gaps exist at numerous levels of global identity and health information exchange. Data on routine immunization already faces deep challenges. Studies show, for example, that despite WHO coverage estimates near 99%, up to 54% of children do not actually receive timely measles vaccinations in Bangladesh1. Widespread gaps in data quality, reporting, and patient identification in routine vaccine delivery disrupt services and presage COVID-19 vaccine delivery challenges in the near future.
The supply of the first generation COVID-19 vaccines will be scarce, and each course must reach the intended recipient. Corruption, leakage, spoilage and even accidental duplications are deadly. Most current COVID-19 vaccine candidates require a two-dose course; patients will need to be reliably identified to ensure appropriate spacing of doses. Further, long-term efficacy remains to be seen and will require accurate, longitudinal patient data. Tracking patient data over time and across service delivery points requires patient identification systems. Patient identification systems will be the hardest to achieve in the places they are needed most. Many low-income countries lack a foundational government-issued ID. About one billion people lack any official civil registration.
We do have some options to face this disturbing scenario and one involves biometric digital identity.
The foundational ID challenge will not be solved in time for the release of a COVID-19 vaccine. However, organizations like Gavi have identified biometric digital identity as a potential lever to bridge the identity gap and ensure accurate data2. Done properly, these systems can be privacy preserving, interoperable, portable, secure, and capable of serving both adult and children's needs. Interoperability standards will ensure these systems can plug into foundational ID programs as coverage expands over the next decade, and privacy-first architecture design is already underway in several projects3.
Biometric immunization registries can deliver both COVID-19 vaccines and serve routine immunizations which are becoming less routine as the pandemics secondary effects become more prominent. We should be developing these architectures now - months before the ramp up of vaccine delivery begins and before further lapses in basic primary health lead to explosions of other vaccine preventable illnesses. Missing this chance could waste significant time, effort, and the chance to build forward-looking infrastructure that serves basic healthcare long into the future.
During the latest Ebola epidemic, a rush of technologies were hastily assembled to track and combat the disease, leading to massive duplication of efforts and half-built tools that were abandoned after the crisis4.
We know what is coming. In the next quarter all attention will be on the allocation, distribution and verification of COVID-19 vaccine delivery. Routine immunizations will be disrupted. Investing in the infrastructure that can support COVID-19 vaccine delivery and routine immunizations, for everyone young and old, can ensure that we are taking advantage of this opportunity amidst the challenges and putting countries on track to fight not only this pandemic, but pressing public health needs for years to come.
Major global stakeholders must convene, collaborate, and collectively invest in global standards, legal infrastructure, common vocabularies and interoperable biometrically-supported digital health technologies. This will pay dividends long after the world’s attention has shifted. If done transparently, this infrastructure can enhance trust in vaccines, something critical to clinical trial enrolment and widespread public adoption.
We have a narrow opportunity to set the stage for fair and sustainable infrastructure across the globe. If done well, we can ensure the promise of the COVID-19 vaccine portfolio leads to future widespread vaccination - and protection - for global populations.
No data are associated with this article.
Views | Downloads | |
---|---|---|
Gates Open Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
Partly
Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Yes
Is the Open Letter written in accessible language?
Yes
Where applicable, are recommendations and next steps explained clearly for others to follow?
Partly
Competing Interests: Some of the contributing authors are with Simprints. I am on the Advisory Board of that company. I do not believe that this constitutes a conflict of interest but am flagging it for transparency.
Reviewer Expertise: ID systems and economic development.
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
No
Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Yes
Is the Open Letter written in accessible language?
Yes
Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: infectious disease epidemiology, respiratory infections, vaccines
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 14 Apr 21 |
read | read |
Version 1 18 Dec 20 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Register with Gates Open Research
Already registered? Sign in
If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research.
We'll keep you updated on any major new updates to Gates Open Research
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)